



NDA 206829/S-002

**SUPPLEMENT APPROVAL**

Cubist Pharmaceuticals, LLC c/o Merck Sharp & Dohme Corp.  
Attention: Sandip Roy, Ph.D.  
Executive Director, Global Regulatory Affairs  
126 E. Lincoln Avenue  
P.O. Box 2000, RY34-B1119  
Rahway, NJ 07065-0900

Dear Dr. Roy:

Please refer to your Supplemental New Drug Application (sNDA) dated December 11, 2015, received December 11, 2015, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zerbaxa (ceftolozane and tazobactam) for injection.

This 'Prior Approval' supplemental new drug application provides for updates to Section 6, subsection 6.1, Clinical Trials Experience, Section 12, subsection 12.4, Microbiology, and Section 13, subsection 13.1, Carcinogenesis, Mutagenesis, Impairment of Fertility, of the package insert.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text. Please note that the highlights must be with ½ inch margins on all sides and between columns per 21 CFR 201.57 (d)(8).

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Maureen Dillon-Parker, Regulatory Project Manager, at (301) 796-0706.

Sincerely,

*{See appended electronic signature page}*

Sumathi Nambiar, MD, MPH  
Director  
Division of Anti-Infective Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SUMATHI NAMBIAR  
09/06/2016